Company intelligence / Profile preview

Cognigenics

Eagle, Idaho, United Statescognigenics.io ↗

Ownership: Private
Development stage: Preclinical

Overview

Cognigenics is in late pre-clinical stage development, working toward phase one trials in late 2024. Their lead product candidate, COGN-201, is entering IND-enabling studies. The company is pursuing breakthrough designation and accelerated review with a goal of market introduction by early 2026, pending FDA approval for clinical trials[1][6].

Therapeutic areas: PsychiatryNeurology
Modalities: RNA-based therapeuticsDNA-based therapeuticsCRISPR-CasAAV-based delivery
Industry: Biotech

Drug pipeline

3 assets

COG-101

Preclinical

2 more assets in the full pipeline.

Request access →

Partnerships

Contract Research Organizations (CROs) for laboratory research[1]

Beyond the preview

Go deeper on Cognigenics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Cognigenics.

Explore the full profile